Pharmaceuticals

Jibeier Pharmaceutical

Jibeier Pharmaceutical released FY2026 Q1 earnings on April 27 After-Market BJT, actual revenue CNY 226.42 M, actual EPS CNY 0.21

Jibeier Pharmaceutical FY2026 Q1 Earnings Release on April 28 After-Market BJT

Jibeier Pharmaceutical to Release FY2025 Earnings on April 28 During-Market (BJT), Forecast Revenue CNY 1.247 B, EPS CNY 1.62

Jibeier Pharmaceutical released FY2025 Q4 earnings on February 27 During-Market (BJT), actual revenue CNY 261.63 M, actual EPS CNY 0.3201

Jibeier Pharmaceutical released FY2025 earnings on February 27 During-Market (BJT), actual revenue CNY 966.07 M (forecast CNY 1.247 B), actual EPS CNY 1.31 (forecast CNY 1.62)

Jibeier Pharmaceutical to Release FY2025 Q3 Earnings on October 31 After-Market (BJT)

Jibeier Pharmaceutical released FY2025 9 Months Earnings on October 17 After-Market (BJT), actual revenue CNY 704.43 M, actual EPS CNY 0.9885

Jibeier Pharmaceutical released FY2025 Q3 earnings on October 17 After-Market BJT, actual revenue CNY 249.52 M, actual EPS CNY 0.2397

Jibeier Pharmaceutical released FY2025 Q2 earnings on August 29 During-Market BJT, actual revenue CNY 253.11 M, actual EPS CNY 0.4987

Jibeier Pharmaceutical released FY2025 Semi-Annual Earnings on August 29 During-Market (BJT), actual revenue CNY 454.92 M, actual EPS CNY 0.75

Jibeier Pharmaceutical to Release FY2025 Semi-Annual Earnings on August 30, 2025 (BJT)

Jibei's New Anti-Tumor Drug Receives Clinical Trial Approval

Jibei ESG Rating Dropped to B

Ji Bei Er Director Hu Tao's Divestiture Plan Completed

Jibeier Pharmaceutical released FY2025 Q1 earnings on April 14 After-Market BJT, actual revenue CNY 201.8 M, actual EPS CNY 0.25

Jibeier Pharmaceutical to Release FY2025 Q1 Earnings on April 15 After-Market BJT

Jibeier Pharmaceutical to release FY2024 earnings on April 15, 2025 (BJT), forecasted revenue 1.037 B CNY, EPS 1.34 CNY

Jibeier Pharmaceutical released FY2024 Q4 earnings on February 27, 2025 (BJT), with actual revenue of CNY 253.33 M and EPS of CNY 0.2228

Jibeier Pharmaceutical released FY2024 annual earnings on February 27, 2025 (BJT), actual revenue CNY 896.53 M (forecast CNY 1.037 B), actual EPS CNY 1.13 (forecast CNY 1.34)

Hu Tao Plans to Reduce Holdings of Jibeier by No More Than 1.00%

688566

Jibeier Pharmaceutical announced that the Phase III clinical trial results of its antidepressant new drug JJH201501 have been released. The trial was designed as a randomized, double-blind, placebo-controlled, and positive-controlled study, with a total of 525 participants. The results showed that the 10mg and 15mg dosage groups had significantly better efficacy in treating depression compared to the placebo group, and were comparable to the 20mg group of hydrobromide vortioxetine tablets

Zhitong

Jibeier Pharmaceutical: Results of Phase III Clinical Trial for New Antidepressant JJH201501 Released

688136

002250

300049

688062

Caitong Securities released a research report indicating that phosphoramidite monomers play a key role in the development of small nucleic acid drugs, and demand is expected to grow significantly in the future. According to predictions from sphericalinsights, global sales of nucleotides will reach USD 730 million in 2023, with China being the largest production market, primarily focused on exports. Small nucleic acid drugs are considered potential treatment options for various diseases due to their unique molecular structure and therapeutic mechanisms, and companies within the supply chains of multinational pharmaceutical companies are expected to benefit from this

SDKX

LIANHE TECHNOLOGY

Furui Co.,Ltd.

Mabwell

Caitong Securities: The demand for phosphonamide monomers will flourish, and multinational pharmaceutical companies' supply chain enterprises are expected to benefit

On October 23rd, Jibeier Pharmaceutical announced that the company recently received the "Approval Notice for the Listing Application of Chemical Raw Materials" issued by the National Medical Products Administration. The name of the chemical raw material is Gatifloxacin, which is the main ingredient in the company's Gatifloxacin eye drops. Gatifloxacin eye drops are mainly used for acute bacterial conjunctivitis caused by sensitive bacteria

Jibeier Pharmaceutical: Application for the listing of the chemical raw material drug Gatifloxacin has been approved

Jibeier Pharmaceutical recently announced that its investigational anti-tumor new drug injectable JJH201601 liposome has received clinical trial approval from the National Medical Products Administration. The drug will be used in clinical trials in combination with cetuximab and/or toripalimab for advanced head and neck squamous cell carcinoma. JJH201601 liposome is a novel compound developed based on a liposome drug development technology platform

Jibeier Pharmaceutical: The investigational anti-tumor new drug injectable JJH201601 liposome has obtained approval for clinical trials

According to the Zhitong Finance APP, Jibeier announced that the share reduction plan of the company's director Hu Tao has been completed, with a total reduction of 1.99 million shares, accounting for 1.00% of the company's total share capital

Jibeier's director Hu Tao has cumulatively reduced his holdings by 1%

Jiangsu Jibeier Robotics Co., Ltd. was established with a registered capital of 51 million RMB, and the legal representative is Geng Zhongyi. The company focuses on the research and development of intelligent robots and artificial intelligence applications, with shareholders including Jiangsu Jibeier Pharmaceutical Co., Ltd. and Tan Chenhang

Donews

Jibeier Pharmaceutical and others established a robotics company with a registered capital of 51 million

Jibeier released its Q1 2025 performance report, with operating revenue of 202 million yuan, a year-on-year increase of 3.90%. The net profit attributable to the parent company was 49.5302 million yuan, a year-on-year decrease of 5.68%; the net profit after deducting non-recurring gains and losses was 49.3108 million yuan, a year-on-year decrease of 4.78%. The basic earnings per share were 0.25 yuan/share

Jibeier released its Q1 2025 performance, with a net profit attributable to the parent company of 49.5302 million yuan, a year-on-year decrease of 5.68%

Jibeier announced its 2024 annual performance, with operating revenue of 897 million yuan, a year-on-year increase of 4.14%; net profit attributable to the parent company of 219 million yuan, a year-on-year increase of 0.11%; net profit excluding non-recurring gains and losses of 215 million yuan, a year-on-year increase of 2.85%; basic earnings per share of 1.13 yuan/share. The company plans to distribute a cash dividend of 2.60 yuan (including tax) for every 10 shares

Jibeier Pharmaceutical released its 2024 annual performance, with a net profit attributable to the parent company of 219 million yuan, a year-on-year increase of 0.11%

According to the Zhitong Finance APP, Jibeier announced that the company's shareholder Nantong Huiji Technology Development Co., Ltd. (referred to as "Huiji Technology") has cumulatively reduced its holdings by 620,000 shares through centralized bidding, accounting for 0.31% of the company's total share capital. This reduction plan has been completed

Jibeier shareholders Hui Ji Technology completed the reduction of 620,000 shares

According to the Zhitong Finance APP, Jibeier disclosed its performance preliminary report for the year 2024. During the reporting period, the company achieved a total operating revenue of 897 million yuan, an increase of 4.14% year-on-year; the net profit attributable to the owners of the parent company was 219 million yuan, a decrease of 0.08% year-on-year

Jibeier's net profit for the year 2024 is 219 million yuan, a year-on-year decrease of 0.08%

Jibeier Pharmaceutical(688566.SH)